[go: up one dir, main page]

IN2012DN05186A - - Google Patents

Download PDF

Info

Publication number
IN2012DN05186A
IN2012DN05186A IN5186DEN2012A IN2012DN05186A IN 2012DN05186 A IN2012DN05186 A IN 2012DN05186A IN 5186DEN2012 A IN5186DEN2012 A IN 5186DEN2012A IN 2012DN05186 A IN2012DN05186 A IN 2012DN05186A
Authority
IN
India
Prior art keywords
amyloids
diseases
disease
detection
treatment
Prior art date
Application number
Other languages
English (en)
Inventor
Jerry Yang
Emmanuel A Theodorakis
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of IN2012DN05186A publication Critical patent/IN2012DN05186A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C07C255/43—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/28—Nitrogen atoms
    • C07D295/30—Nitrogen atoms non-acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/24—Radicals substituted by singly bound oxygen or sulfur atoms esterified
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN5186DEN2012 2009-12-10 2010-12-10 IN2012DN05186A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28547009P 2009-12-10 2009-12-10
PCT/US2010/059952 WO2011072257A2 (fr) 2009-12-10 2010-12-10 Agents de liaison aux amyloïdes

Publications (1)

Publication Number Publication Date
IN2012DN05186A true IN2012DN05186A (fr) 2015-10-23

Family

ID=44146211

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5186DEN2012 IN2012DN05186A (fr) 2009-12-10 2010-12-10

Country Status (25)

Country Link
US (3) US8940918B2 (fr)
EP (1) EP2509940B1 (fr)
JP (1) JP5591946B2 (fr)
KR (3) KR20180041767A (fr)
CN (2) CN105669597B (fr)
AU (1) AU2010327918B2 (fr)
BR (1) BR112012013810B1 (fr)
CA (1) CA2783466C (fr)
CY (1) CY1116487T1 (fr)
DK (1) DK2509940T3 (fr)
ES (1) ES2546063T3 (fr)
HR (1) HRP20150854T1 (fr)
HU (1) HUE027199T2 (fr)
IN (1) IN2012DN05186A (fr)
ME (1) ME02194B (fr)
MX (1) MX347591B (fr)
NZ (1) NZ600459A (fr)
PL (1) PL2509940T3 (fr)
PT (1) PT2509940E (fr)
RS (1) RS54158B1 (fr)
RU (1) RU2517174C2 (fr)
SG (1) SG181561A1 (fr)
SI (1) SI2509940T1 (fr)
SM (1) SMT201500216B (fr)
WO (1) WO2011072257A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013180815A1 (fr) * 2012-05-30 2013-12-05 University Of Tennessee Research Foundation Composés pour des réactions de formation d'amide
US9588129B2 (en) 2013-03-15 2017-03-07 Amira Medical Technologies Inc. Methods for analyzing blood to detect diseases associated with abnormal protein aggregation
AR098232A1 (es) * 2013-10-31 2016-05-18 Cognoptix Inc Métodos de preparación de una formulación oftálmica y usos de la misma
WO2015072964A1 (fr) * 2013-11-12 2015-05-21 Cognoptix, Inc. Procédé de mesure de fluorescence dans le tissu oculaire
JP2017512834A (ja) 2014-03-19 2017-05-25 アミディス・ダイアグノスティックス・インコーポレイテッド アミロイド標的剤及びその使用方法
CA2960723A1 (fr) * 2014-09-12 2016-03-17 Amydis Diagnostics, Inc. Compositions in vitro comprenant un echantillon humain et un agent ciblant les substances amyloides
US11286233B2 (en) 2017-05-09 2022-03-29 Ambient Photonics, Inc. Stilbene derivatives for the treatment of CNS and other disorders
JP7381500B2 (ja) * 2018-05-31 2023-11-15 アミディス， インコーポレイテッド 外傷性脳損傷を検出するための組成物および方法
EP3873466B1 (fr) * 2018-11-02 2024-07-24 Amydis, Inc. Composés de phosphate pour détecter des troubles neurologiques
KR102240400B1 (ko) 2020-11-19 2021-04-15 한국원자력연구원 베타-아밀로이드 검출용 수용성 화합물
US20240165274A1 (en) * 2021-03-12 2024-05-23 Amydis, Inc. Methods of detecting systemic amyloidosis via binding to misfolded or aggregated protein
CN115322165A (zh) * 2022-09-30 2022-11-11 镇江百单医疗生物科技有限公司 近红外荧光探针成像肝纤维化中亚铁离子的动态波动

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2583614A (en) * 1950-05-13 1952-01-29 Eastman Kodak Co Acylated methine dye compounds
US2798090A (en) * 1953-03-02 1957-07-02 Eastman Kodak Co Process for preparing benzalaniline-3-sulfonic acid compounds
US3074971A (en) * 1959-01-23 1963-01-22 Gen Aniline & Film Corp alpha-cyanocinnamic acid esters
US3149146A (en) * 1960-03-09 1964-09-15 Gen Aniline & Film Corp Alpha-cyano-2-alkenoxy-1-naphthaleneacrylic acid esters
FR1321641A (fr) * 1962-03-08 1963-03-22 Gen Aniline & Film Corp Nouvelles compositions absorbantes de rayons ultraviolets
BE794010A (fr) * 1972-01-13 1973-05-02 Du Pont Colorants cationiques de couleur jaune-vert
DE2714653C3 (de) * 1977-04-01 1980-10-30 Bayer Ag, 5090 Leverkusen Kationische Styrylfarbstoffe und Verfahren zum Färben mit diesen Farbstoffen
DE2942185A1 (de) * 1979-10-18 1981-04-30 Basf Ag, 6700 Ludwigshafen Basische farbstoffe
JPS5815912A (ja) * 1981-07-22 1983-01-29 Ss Pharmaceut Co Ltd 消炎鎮痛剤
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JPS63163826A (ja) * 1986-12-26 1988-07-07 Idemitsu Kosan Co Ltd 有機非線型光学材料
DE3905916A1 (de) * 1989-02-25 1990-08-30 Basf Ag Verwendung von derivaten des n-phenyl-3,4,5,6-tetrahydrophthalimids zur desikkation und abszission von pflanzenorganen
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
DE4430691A1 (de) * 1994-08-30 1996-03-07 Bayer Ag Elektrolumineszierende Anordnungen und deren Verwendung
GB2401363B (en) * 2002-01-18 2005-10-12 Hospital For Sick Children Compounds for modulating cell proliferation
GB0228410D0 (en) * 2002-12-05 2003-01-08 Glaxo Group Ltd Novel Compounds
ZA200507321B (en) * 2003-03-05 2007-03-28 Celgene Corp Diphenylethylene compounds and uses thereof
WO2005073697A1 (fr) * 2004-01-20 2005-08-11 The Curators Of The University Of Missouri Capteur de contrainte locale d'ecoulement et de cisaillement fonde sur l'utilisation de rotors moleculaires
US7598419B2 (en) * 2004-03-26 2009-10-06 Hsc Research And Development Limited Partnership Compounds for modulating cell proliferation
CA2586334A1 (fr) * 2004-11-16 2006-06-08 Neurochem (International) Limited Composes pour le traitement de maladies associees au snc et a la proteine amyloide
WO2007011834A2 (fr) 2005-07-15 2007-01-25 The Regents Of The University Of California Composes et procede pour diagnostiquer et traiter les maladies associees aux amyloides
EP2049253B1 (fr) 2006-07-31 2019-09-11 Basf Se procede integre comprenant la dehydratation utilisant un catalyseur de ruthenium et regeneration correspondante
FR2905009A1 (fr) * 2006-08-18 2008-02-22 Servier Lab Methode de criblage de composes aux proprietes anti-amyloide
CN101209976B (zh) * 2006-12-29 2012-01-11 中国人民解放军军事医学科学院毒物药物研究所 取代的酒石酸衍生物及其用于制备β-分泌酶抑制剂的用途
EP2217930B1 (fr) * 2007-10-24 2013-03-06 Tallinn University Of Technology Procédé de criblage à grande cadence à base de maldi ms pour des substances qui inhibent l'agrégation des peptides bêta-amyloïdes de la maladie d'alzheimer

Also Published As

Publication number Publication date
US9551722B2 (en) 2017-01-24
BR112012013810B1 (pt) 2022-01-11
AU2010327918B2 (en) 2014-01-16
BR112012013810A2 (pt) 2020-08-25
EP2509940A4 (fr) 2013-04-17
CN105669597B (zh) 2019-05-07
PL2509940T3 (pl) 2015-11-30
US8940918B2 (en) 2015-01-27
KR20180041767A (ko) 2018-04-24
DK2509940T3 (en) 2015-07-20
US20150177262A1 (en) 2015-06-25
HK1225729A1 (zh) 2017-09-15
CA2783466A1 (fr) 2011-06-16
CY1116487T1 (el) 2017-03-15
HUE027199T2 (en) 2016-08-29
EP2509940B1 (fr) 2015-06-10
EP2509940A2 (fr) 2012-10-17
SMT201500216B (it) 2015-10-30
WO2011072257A2 (fr) 2011-06-16
KR101849680B1 (ko) 2018-04-17
MX2012006552A (es) 2012-08-23
HK1177930A1 (en) 2013-08-30
SI2509940T1 (sl) 2015-09-30
CA2783466C (fr) 2019-09-24
ME02194B (me) 2016-02-20
CN103201258B (zh) 2016-01-27
HRP20150854T1 (hr) 2015-09-25
PT2509940E (pt) 2015-09-24
RU2517174C2 (ru) 2014-05-27
US20170315137A1 (en) 2017-11-02
KR20190109594A (ko) 2019-09-25
CN103201258A (zh) 2013-07-10
KR102079160B1 (ko) 2020-02-19
NZ600459A (en) 2014-01-31
RU2012128798A (ru) 2014-01-20
JP2013513619A (ja) 2013-04-22
JP5591946B2 (ja) 2014-09-17
ES2546063T3 (es) 2015-09-18
AU2010327918A1 (en) 2012-06-21
WO2011072257A3 (fr) 2011-10-20
RS54158B1 (sr) 2015-12-31
KR20120104306A (ko) 2012-09-20
SG181561A1 (en) 2012-07-30
CN105669597A (zh) 2016-06-15
US20120302603A1 (en) 2012-11-29
MX347591B (es) 2017-05-03

Similar Documents

Publication Publication Date Title
IN2012DN05186A (fr)
WO2011045415A3 (fr) Nouveaux agents d'imagerie et leur utilisation pour le diagnostic in vivo de maladies neurodégénératives, notamment la maladie d'alzheimer et les maladies dérivées
PL2104682T3 (pl) Diagnostyka i leczenie choroby Alzheimera i innych chorób neurodegeneracyjnych
IL245889A0 (en) Sulfonamide derivatives as bcl-2-selective apoptosis inducers for the treatment of cancer and immune diseases
WO2013033037A3 (fr) Nouveaux composés d'antiprion
IL216399A0 (en) Pharmaceutical composition for the treatment of heart diseases
EP2429992A4 (fr) Traitement du trouble cognitif léger et de la maladie d'alzheimer
IL208926A0 (en) Use of epothelone d in treating tau-associated diseases including alzheimer's disease
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
EP2568811A4 (fr) Traitement du tcl et de la maladie d'alzheimer
WO2011044537A9 (fr) Procédés pour le traitement de la maladie d'alzheimer
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
WO2010105035A9 (fr) Prévention, traitement, et diagnostic de la maladie d'alzheimer par exposition à un champ électromagnétique
GB0904427D0 (en) Treatment of diseases related to hyperactivity of the complement system
GB2473579A (en) Stat3 and TYK2 as drug targets for neurodegenerative diseases
IL237730B (en) Treatment of mild and moderate Alzheimer's disease
DE102009018133A8 (de) Pharmazeutische Zusammensetzung zur Behandlung von dermatologischen Autoimmunerkrankungen
ZA201402477B (en) Compounds for use in the treatment of alzheimer's disease
PL2565184T3 (pl) Środek terapeutyczny i środek zapobiegawczy przeciwko chorobie alzheimera
EP2413696A4 (fr) Compositions pour le traitement de la maladie d'alzheimer
NZ609924A (en) Porphyrin treatment of neurodegenerative diseases
GB201206984D0 (en) New therapeutic use
HK1183408A (en) Treatment of mci and alzheimer's disease
EP2613849A4 (fr) Radiothérapie pour traiter la maladie d'alzheimer
GB201101088D0 (en) L-carnosine and cinnamon extract for the treatment of Alzheimer's Disease